Apolipoprotein E variants correlate with the clinical presentation of paediatric inflammatory bowel disease: A cross-sectional study

Table 5 Summary of relevant findings depending on apolipoprotein E genotypes and alleles

Variables median (IQR) or n (%)	n	ε3/ε3	APOEε2-positive	APOEε4-positive	P value
IBD
Albumin level at worst flare in g/dL	327	3.9 (3.4-4.3)	4.0 (3.9-4.5)	4.1 (3.8-4.4)	0.0176a
CRP at worst flare in mg/L	347	7.7 (1.9-31.3)	4.3 (1.1-28.3)	3.2 (0.5-16.7)	0.0146b
Age at first surgery in yr	36	14.5 (11.7-16.7)	9.5 (7.7-11.4)	14.9 (14.0-15.6)	0.0378
Days of hospitalisation for relapse, per 1 yr of the disease	230	4.7 (1.6-8.3)	2.2 (0.7-4.8)	6.1 (1.7-8.7)	0.0440c
CD
Albumin level at worst flare in g/dL	327	3.9 (3.4-4.1)	3.9 (3.8-4.4)	4.4 (3.6-4.3)	0.0363
PCDAI at diagnosis	190	35 (25-50)	25 (20-35)	30 (25-45)	0.0204c
Height at diagnosis, z score	378	-0.47 [(-1.43)-0.32]	-0.16 [(-0.85)-0.61]	0.00 [(-1.10)-0.96]	0.0482
UC
CRP at diagnosis in mg/L	386	2.5 (0.7-12.2)	3.8 (0.8-7.3)	1.1 (0.2-8.2)	0.0435
CRP at worst flare in mg/L	347	3.7 (1.1-19.0)	2.1 (1.8-7.3)	0.9 (0.3-3.6)	0.0013
Age at first biological treatment	151	11.5 (7.9-14.6)	15.7 (15.3-15.7)	10.7 (4.8-15.5)	0.0432
E2 at diagnosis	192	16 (13.6)	8 (40.0)	9 (18.0)	0.0160

^a Post hoc APOEε3ε3 vs APOEε2-positive P = 0.0383 (Bonferroni and Holm); APOEε3ε3 vs APOEε4-positive P = 0.0417 (Bonferroni) and P = 0.0383 (Holm).

^b Post hoc APOEε3ε3 vs APOEε4-positive P = 0.0056 (Bonferroni and Holm).

^c APOEε3ε3 vs APOEε2-positive P = 0.0534 (Bonferroni) and P = 0.0356 (Holm), APOEε2-positive vs APOEε4-positive P = 0.0216 (Bonferroni and Holm). CD: Crohn’s disease; CRP: C-reactive protein; IBD: Inflammatory bowel disease; PCDAI: Pediatric Crohn’s Disease Activity Index; UC: Ulcerative colitis.